WANG Feng. Influence of linagliptin on the blood glucose change in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2014, (13): 99-101. DOI: 10.7619/jcmp.201413033
Citation: WANG Feng. Influence of linagliptin on the blood glucose change in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2014, (13): 99-101. DOI: 10.7619/jcmp.201413033

Influence of linagliptin on the blood glucose change in patients with type 2 diabetes mellitus

More Information
  • Published Date: September 10, 2014
  • Objective To investigate the influence of linagliptin on the blood glucose change in patients with type 2 diabetes mellitus (T2DM)and to evaluate its safety.Methods A total of 98 patients diagnosed with T2DM admitted in our hospital were randomly divided into treatment group and control group,49 cases for each.Control group was treated with insulin glargine concomitant with dimethyldiguanide,on which basis treatment group was added with 5 mg /d linagliptin.Fast-ing plasma glucose (FPG),plasma glucose 2 h after meals (2hPG),glycosylated hemoglobin (HbAlc),body mass index (BMI)and adverse response rate before and 12 weeks after treatment were compared between two groups.Results After 12 weeks treatment,FPG,2hPG and HbAlc reduced evidently than treatment before,and were more lower in treatment group than in control group (P <0.05),while BMI had no significant difference before and after treatment in both groups (P > 0.05 ).The main adverse responses included nasopharyngitis,hypoglycemia, headache,gastrointestinal reactions and upper respiratory infection,in which only upper respiratory infection rate was significantly different between two groups (P <0.05).Conclusion linagliptin plus insulin glargine concomitant with dimethyldiguanide can effectively control blood glucose changes in patients with T2DM,which deserves to be widely used in clinic.
  • 中国老年学学会老年医学会老年内分泌代谢专业委员会, 老年糖尿病诊疗措施专家共识编写组. 老年糖尿病诊疗措施专家共识(2013 年版) [J]. 中华内科杂志, 2014(3):243.
    Rosenstock J, Dal ey G, Maasi-benedetti G, et a1. Re-duced hypoglycemia risk with insulin glargine:a meta-anal-ysis comparing insulin glargine with human NPH insulin in type 2 diabetes [J]. DIABETES CARE, 2005(4):950.
    Amori R, Lau J, Pittas A. Efficacy and safety of incertin therapy in type 2 diabetes [J]. JAMA:the Journal of the American Medical Association, 2007(2):194.
    Holman R R, Thome K I, Farmer A J. Addition of biphasic, prandialor basal insulin to oral therapy in type 2 dia-betes [J]. N Ensl J Med, 2007, (17):1716.
    Park C Y, Kang J G, Chon S. Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrol ed Patients with Type 2 Diabetes [J]. PLoS One, 2014(3):e87799.
    Nauck M A. Incretin-based therapies for type 2 diabetes mel itus:properties, functions, and clinical implications [J]. American Journal of Medicine, 2011, (1 Suppl):S3.
    Forst T, Uhlig-Laske B, Ring A. The oral DP-4inhibitor linagliptin significantly lowers HbA1c after 4 weeks oftreatment in patients with type 2 diabetes mel itus [J]. Di-abetesObes Metab, 2011(6):542.
    Graefe-Mody U, Rose P, Retlich S. Pharmacokinet-ics of linagliptin in subjects with hepatic impairment [J]. British Journal of Clinical Pharmacology(England), 2012, (10):1365.
    Schernthaner G, Barnett A H, Emser A. Safety and tolerability of linagliptin:a pooled analysis of data from ran-domized control ed trials in 3572 patients with type 2diabetes mel itus [J]. Diabetes Obesity & Metabolism, 2012(5):470.
    del P S, Baenett A, Huisman H. Effect of linagliptin monotherapy on glycaemic control and markers of β-cellfunction in patients with inadequately control ed type 2diabetes:a randomized control ed trial [J]. Diabetes Obesity & Metabolism, 2011(3):258.
    Taskinen M R, Rosenstock J, Tamminen I. Safety and efficacy of linagliptin as add-on therapy to metformin inpa-tients with type 2 diabetes:a randomized, double-blind, placebo-control ed study [J]. Diabetes Obesity & Metabolism, 2011(1):65.
    Gomis R, Espadero R M, Jones R. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately control ed type 2diabetes:a ran-domized, double-blind, placebo-control ed study [J]. Dia-betes Obes Metab, 2011(7):653.

Catalog

    Article views (182) PDF downloads (0) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return